T1	Participants 1301 1321	66 patients enrolled
T3	Participants 1005 1124	Patients were randomized to receive either clodronate 1,600 mg/day for one year or identical placebo-containing tablets
T2	Participants 784 985	Sixty-six patients with poorly responsive tumors such as non-small cell lung cancer (NSCLC), bladder cancer, gastrointestinal cancers, kidney cancer, melanoma and metastatic carcinoma of unknown origin
